Cargando…

NPY Gene Methylation in Circulating Tumor DNA as an Early Biomarker for Treatment Effect in Metastatic Colorectal Cancer

SIMPLE SUMMARY: Despite several limitations, imaging is still the gold standard in evaluating the treatment effect in metastatic colorectal cancer, and the best response is often achieved several months after treatment start. The present study investigated methylated circulating tumor DNA (ctDNA) in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raunkilde, Louise, Hansen, Torben Frøstrup, Andersen, Rikke Fredslund, Havelund, Birgitte Mayland, Thomsen, Caroline Brenner, Jensen, Lars Henrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496936/ https://www.ncbi.nlm.nih.gov/pubmed/36139621 http://dx.doi.org/10.3390/cancers14184459

Ejemplares similares

NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer
por: Jensen, Lars Henrik, et al.
Publicado: (2019)

Re‐exposure to immunotherapy in metastatic colon cancer: A case report
por: Hamre, Tonje Riise, et al.
Publicado: (2021)

The Clinical Impact of Methylated Homeobox A9 ctDNA in Patients with Non-Resectable Biliary Tract Cancer Treated with Erlotinib and Bevacizumab
por: Andersen, Line Bechsgaard, et al.
Publicado: (2022)

Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab
por: Hansen, Torben Frøstrup, et al.
Publicado: (2017)

The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer
por: Wen, Sara Witting Christensen, et al.
Publicado: (2021)

Methylated Circulating Tumor DNA in Blood as a Tool for Diagnosing Lung Cancer: A Systematic Review and Meta-Analysis
por: Borg, Morten, et al.
Publicado: (2023)

Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer
por: Thomsen, Caroline B., et al.
Publicado: (2020)

Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: a phase 2, single-center, open-label, and non-comparative study
por: Jensen, Lars Henrik, et al.
Publicado: (2023)

Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer()
por: Hansen, Torben Frøstrup, et al.
Publicado: (2019)

NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors
por: Wen, Sara Witting Christensen, et al.
Publicado: (2023)

Pseudoprogression during treatment with pembrolizumab followed by rechallenge with chemotherapy in metastatic colorectal cancer: A case report
por: Trabjerg, Natacha Dencker, et al.
Publicado: (2019)

Validating Methylated HOXA9 in Bronchial Lavage as a Diagnostic Tool in Patients Suspected of Lung Cancer
por: Wen, Sara W. C., et al.
Publicado: (2021)

Association between the expression of microRNAs and the response of patients with locally advanced rectal cancer to preoperative chemoradiotherapy
por: Eriksen, Anne Haahr Mellergaard, et al.
Publicado: (2017)

MicroRNA Expression Profiling to Identify and Validate Reference Genes for the Relative Quantification of microRNA in Rectal Cancer
por: Eriksen, Anne Haahr Mellergaard, et al.
Publicado: (2016)

Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer
por: Spindler, Karen Lise Garm, et al.
Publicado: (2015)

Intratumoral Heterogeneity of MicroRNA Expression in Rectal Cancer
por: Eriksen, Anne Haahr Mellergaard, et al.
Publicado: (2016)

Natural killer cell activity as a biomarker for the diagnosis of lung cancer in high-risk patients
por: Borg, Morten, et al.
Publicado: (2022)

Reporting on circulating tumor DNA monitoring in metastatic cancer—From clinical validity to clinical utility
por: Brenner Thomsen, Caroline, et al.
Publicado: (2022)

Circulating DNA and frequency of colorectal cancer brain metastases in a presumed high-risk group
por: Callesen, Louise Bach, et al.
Publicado: (2023)

Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer
por: Faaborg, Louise, et al.
Publicado: (2022)

The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer
por: Thomsen, Caroline Emilie B., et al.
Publicado: (2017)

The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer
por: Hansen, Torben Frøstrup, et al.
Publicado: (2012)

Nonplatinum‐based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A population‐based Danish anal cancer group study
por: Truelsen, Christina Glismand, et al.
Publicado: (2021)

Receptor-specific recognition of NPY peptides revealed by structures of NPY receptors
por: Tang, Tingting, et al.
Publicado: (2022)

Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data
por: Hansen, Torben Frøstrup, et al.
Publicado: (2021)

NPY's mixed messages
por: Van Epps, Heather L.
Publicado: (2005)

A role for NPY-NPY2R signaling in albuminuric kidney disease
por: Lay, Abigail C., et al.
Publicado: (2020)

Intensified Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Anus—A Population-Based Experience from the Danish Anal Cancer Group
por: Wind, Karen Lycke, et al.
Publicado: (2021)

Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts
por: Hansen, Torben Frøstrup, et al.
Publicado: (2018)

Drug Repositioning Based on the Reversal of Gene Expression Signatures Identifies TOP2A as a Therapeutic Target for Rectal Cancer
por: Carvalho, Robson Francisco, et al.
Publicado: (2021)

MicroRNA-126 and epidermal growth factor-like domain 7 predict recurrence in patients with colon cancer treated with neoadjuvant chemotherapy
por: Hansen, Torben Frøstrup, et al.
Publicado: (2019)

Cell Free Methylated Tumor DNA in Bronchial Lavage as an Additional Tool for Diagnosing Lung Cancer—A Systematic Review
por: Wen, Sara Witting Christensen, et al.
Publicado: (2022)

The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer
por: Blomberg, Kristian, et al.
Publicado: (2021)

The Novel Methylation Biomarker NPY5R Sensitizes Breast Cancer Cells to Chemotherapy
por: Liu, Jiazhou, et al.
Publicado: (2022)

Quantification of Cell-Free HER-2 DNA in Plasma from Breast Cancer Patients: Sensitivity for Detection of Metastatic Recurrence and Gene Amplification
por: Sørensen, Patricia Diana, et al.
Publicado: (2015)

Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer
por: Roperch, Jean-Pierre, et al.
Publicado: (2013)

The Role of NPY in the Regulation of Bone Metabolism
por: Chen, Qing-Chang, et al.
Publicado: (2022)

Comparison of Mutated KRAS and Methylated HOXA9 Tumor-Specific DNA in Advanced Lung Adenocarcinoma
por: Wen, Sara W. C., et al.
Publicado: (2020)

The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal
por: Dizdarevic, Edina, et al.
Publicado: (2022)

The role of NPY in expression and extinction of conditioned fear
por: Verma, Dilip, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_moentmr8aq19qidjb6vscf5qt1